42 Stocks Moving In Monday's Mid-Day Session

Gainers

• Medley Management Inc MDLY shares surged 29.5% to $3.0801 after the company announced a merger agreement with Sierra Income. Medley Capital shareholders will receive 0.67 shares of Sierra stock and $2.96 per share in cash.
• NovaBay Pharmaceuticals, Inc. NBY rose 28.4% to $1.31 after the company reported better-than-expected Q2 sales results.
• Pieris Pharmaceuticals, Inc. PIRS rose 17.9% to $5.60. Pieris Pharma said on July 26, European Respiratory Society announced acceptance of late-breaking presentation of company's Phase 1 study of PRS-060.
• Pluristem Therapeutics Inc. PSTI climbed 14.4% to $5.79.
• Mylan N.V. MYL rose 12.6% to $20.78 after the company announced a business combination with Pfizer's Upjohn division. The company also reported better-than-expected Q2 results.
• TCR2 Therapeutics Inc. TCRR shares rose 12.3% to $15.35 after gaining 5.15% on Friday.
• Research Frontiers Incorporated REFR gained 11.3% to $3.35.
• Leo Holdings Corp. LHC climbed 10.6% to $10.19.
• Soligenix, Inc. SNGX shares rose 10.3% to $1.1686 after the company received European patents for Oral BDP in the treatment of acute radiation injury of the gastrointestinal tract.
• VISTA OIL & GAS/S ADR VIST gained 9.5% to $9.96.
• CEL-SCI Corporation CVM gained 9.3% to $7.76.
• Orion Energy Systems, Inc. OESX climbed 9% to $3.1487.
• Tile Shop Holdings, Inc. TTS gained 7.3% to $2.95.
• Niu Technologies NIU rose 6.9% to $6.82. Niu Technologies is expected to release Q2 earnings on August 23, 2019.
• Tower Semiconductor Ltd. TSEM rose 5.3% to $19.29 after the company reported better-than-expected Q2 EPS and sales results.
• Booz Allen Hamilton Holding Corporation BAH rose 3.4% to $71.51 after the company reported upbeat Q1 earnings results.

Check out these big penny stock gainers and losers

Losers

• Lexicon Pharmaceuticals, Inc. LXRX shares dipped 73% to $1.54 after the company received a written notice from Sanofi SNY terminating the agreement for the development and commercialization of the company's Diabetes drug candidate Sotagliflozin.
• iPic Entertainment Inc. IPIC shares fell 43.2% to $1.1525.
• On Deck Capital Inc ONDK dropped 20.2% to $3.16 after the company reported worse-than-expected Q2 EPS results and narrowed its FY19 sales guidance.
• Insperity Inc NSP dropped 18.1% to $118.50 after the company issued Q3 EPS guidance below analyst estimates.
• BP Prudhoe Bay Royalty Trust BPT dipped 13.2% to $7.88.
• Oil States International, Inc. OIS fell 12.3% to $12.19 following downbeat Q2 results.
• Avinger, Inc. AVGR tumbled 12.3% to $2.0701.
• Exact Sciences Corporation EXAS fell 12% to $103.73 after the company announced it will acquire Genomic Health for $72 per share in cash and stock.
• Neovasc Inc. NVCN dipped 10.7% to $2.43.
• Fang Holdings Limited SFUN shares dropped 10.6% to $2.2250.
• GAIN Capital Holdings, Inc. GCAP shares declined 10.2% to $4.22.
• Alterity Therapeutics Ltd ATHE fell 9.4% to $1.06 after the company announced the completion of its Phase 1 clinical trial for PBT434. The drug was safe and well-tolerated, with adverse event rates comparable to placebo.
• Harvard Bioscience, Inc. HBIO shares tumbled 8.9% to $2.46.
• The Joint Corp. JYNT dropped 8.7% to $18.65.
• Upland Software, Inc. UPLD shares dipped 8.7% to $43.60.
• Cooper Tire & Rubber Company CTB fell 8.7% to $27.82 after the company reported worse-than-expected Q2 results.
• Core Laboratories N.V CLB shares declined 8.5% to $48.54.
• Range Resources Corporation RRC fell 8.2% to $4.7450.
• Flexible Solutions International Inc. FSI shares fell 8.2% to $2.9739.
• Neuralstem, Inc. CUR shares tumbled 8% to $2.20 after dropping 35.8% on Friday.
• Rekor Systems, Inc. REKR shares fell 6.7% to $4.98 after rising 16.85% on Friday.
• Vermilion Energy Inc VET fell 6.7% to $17.22 after the company reported worse-than-expected Q2 EPS results.
• Ra Pharmaceuticals, Inc. RARX fell 5.9% to $33.95. Raymond James downgraded Ra Pharmaceuticals from Strong Buy to Market Perform.
• DISH Network Corp DISH fell 4.4% to $37.77 after Barclays downgraded the stock from Equal-Weight to Underweight and announced a price target of $31 per share.
• Myriad Genetics, Inc. MYGN dropped 4.3% to $27.70 after Needham downgraded the company from Strong Buy to Hold.
• Mercury General Corporation MCY dropped 4.3% to $59.49 after the company reported worse-than-expected Q2 EPS and sales results.